GLOBRYTE: A Phase III, Open-label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma

被引：0
|
作者：
Phillips, Tycel [1 ]
Matasar, Matthew [2 ]
Eyre, Toby A. [3 ]
Gine, Eva [4 ]
de L'Etang, Audrey Filezac [5 ]
Byrne, Ben [6 ]
Lundberg, Linda [5 ]
Padovani, Alejandra [5 ]
Boetsch, Christophe [5 ]
Bottos, Alessia [5 ]
Qayum, Naseer [6 ]
机构：
[1] City Hope Natl Med Ctr, Duarte, CA USA
[2] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[3] Oxford Univ Hosp NHS Trust, Oxford, England
[4] Hosp Clin Barcelona, Barcelona, Spain
[5] F Hoffmann La Roche Ltd, Basel, Switzerland
[6] Roche Prod Ltd, Welwyn Garden City, Herts, England
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
MCL; clinical trials; non-Hodgkin lymphoma; bispecific antibody therapy; adverse events; mantle cell lymphoma; phase; 3;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MCL-339
引用
收藏
页码：S515 / S515
页数：1
相关论文
共 50 条
  • [21] Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial
    Jerkeman, Mats
    Eskelund, Christian Winther
    Hutchings, Martin
    Raty, Riikka
    Wader, Karin Fahl
    Laurell, Anna
    Toldbod, Helle
    Pedersen, Lone Bredo
    Niemann, Carsten Utoft
    Dahl, Christina
    Kuitunen, Hanne
    Geisler, Christian H.
    Gronbaek, Kirsten
    Kolstad, Arne
    LANCET HAEMATOLOGY, 2018, 5 (03): : E109 - E116
  • [22] An open label, single arm, multicenter phase II study of the efficacy and safety of LP-168 monotherapy for relapsed or refractory mantle cell lymphoma.
    Song, Yuqin
    Tang, Xiaoqiong
    Cai, Qingqing
    Liu, Lihong
    Jing, Hongmei
    Jiang, Ming
    Sun, Xiuhua
    Wu, Jianqiu
    Yang, Yu
    Wu, Huijing
    Peng, Zhigang
    Ding, Kaiyang
    Yi, Shuhua
    Yan, Xiaojing
    Wu, Guowu
    Wu, Yudan
    Cui, Jie
    Ou, Pengju
    Tan, Fenlai
    Zhu, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open-label, registration directed Phase II study
    Fowler, Nathan H.
    Samaniego, Felipe
    Jurczak, Wojciech
    Lech-Maranda, Ewa
    Ghosh, Nilanjan
    Anz, Bertrand
    Patten, Piers
    Reeves, James A.
    Leslie, Lori A.
    Smolewski, Piotr
    Chavez, Julio C.
    Ghia, Paolo
    Tarella, Corrado
    Burke, John M.
    Sharman, Jeff
    Kolibaba, Kathryn
    O'Connor, Owen A.
    Cheah, Chan Y.
    Miskin, Hari P.
    Sportelli, Peter
    Weiss, Michael S.
    Zinzani, Pier Luigi
    CANCER RESEARCH, 2019, 79 (13)
  • [24] Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study
    Phillips, Tycel Jovelle
    Carlo-Stella, Carmelo
    Morschhauser, Franck
    Bachy, Emmanuel
    Crump, Michael
    Trneny, Marek
    Bartlett, Nancy L.
    Zaucha, Jan
    Wrobel, Tomasz
    Offner, Fritz
    Humphrey, Kathryn
    Relf, James
    de L'Etang, Audrey Filezac
    Carlile, David J.
    Byrne, Ben
    Qayum, Naseer
    Lundberg, Linda
    Dickinson, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (03)
  • [25] A Multicenter, Open-Label, Phase 1b/2 Study to Evaluate the Effects of Maplirpacept in Combination with Glofitamab in People with Relapsed or Refractory Diffuse Large B Cell Lymphoma
    Luscan, Gerald
    Paccagnella, Luisa
    Patel, Krish
    BLOOD, 2023, 142
  • [26] Acalabrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): Results of a phase 2, multicenter, open-label trial.
    Budde, L. Elizabeth
    Coleman, Morton
    Stevens, Don A.
    Ma, Shuo
    Patti, Caterina
    Levy, M. Yair
    Lossos, Izidore S.
    Geethakumari, Praveen Ramakrishnan
    Lam, Selay
    Calvo, Roser
    Higgins, Kara
    Strati, Paolo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study
    Deng, Lijuan
    Li, Zhiming
    Zhang, Huilai
    Huang, Haiwen
    Hu, Jianda
    Liu, Lihong
    Liu, Ting
    Jin, Jie
    Zhu, Zunmin
    Li, Wenyu
    Huang, Zhenqian
    Huang, Wenrong
    Zhou, Keshu
    Yang, Haiyan
    Zhang, Mingzhi
    Ding, Kaiyang
    Zhou, Hui
    Hu, Yu
    Shuang, Yuerong
    Cao, Junning
    Gao, Sujun
    Li, Dengju
    Sun, Zimin
    Zhang, Qingyuan
    Yi, Shuhua
    Ji, Chunyan
    Zhang, Liansheng
    Hou, Cheng
    Du, Yue
    Wang, Weige
    Zhao, Renbin
    Song, Yuqin
    Zhu, Jun
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (11) : 1742 - 1750
  • [28] Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study
    Huang, Huiqiang
    Zhu, Jun
    Yao, Ming
    Kim, Tae Min
    Yoon, Dok Hyun
    Cho, Seok-Goo
    Eom, Hyeon Seok
    Lim, Soon Thye
    Yeh, Su-peng
    Song, Yuqin
    Kwong, Yok Lam
    Kim, Jin Seok
    Jin, Jie
    Shi, Yuankai
    Kim, HyeJin
    Qing, Min
    Zhou, Tianyuan
    Gao, Grace
    Dong, Zongqi
    Qi, Ming
    Kim, Won Seog
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
  • [29] Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study
    Huiqiang Huang
    Jun Zhu
    Ming Yao
    Tae Min Kim
    Dok Hyun Yoon
    Seok-Goo Cho
    Hyeon Seok Eom
    Soon Thye Lim
    Su-peng Yeh
    Yuqin Song
    Yok Lam Kwong
    Jin Seok Kim
    Jie Jin
    Yuankai Shi
    HyeJin Kim
    Min Qing
    Tianyuan Zhou
    Grace Gao
    Zongqi Dong
    Ming Qi
    Won Seog Kim
    Journal of Hematology & Oncology, 14
  • [30] Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
    Fisher, Richard I.
    Bernstein, Steven H.
    Kahl, Brad S.
    Djulbegovic, Benjamin
    Robertson, Michael J.
    de Vos, Sven
    Epner, Elliot
    Krishnan, Amrita
    Leonard, John P.
    Lonial, Sagar
    Stadtmauer, Edward A.
    O'Connor, Owen A.
    Shi, Hongliang
    Boral, Anthony L.
    Goy, Andre
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (30) : 4867 - 4874
12345